Farletuzumab
Farletuzumab
Farletuzumab (pronunciation: far-le-too-zoo-mab) is a humanized monoclonal antibody designed for the treatment of cancer. It is developed by Morphotek, a subsidiary of Eisai Co.
Etymology
The name "Farletuzumab" is derived from the company's name "Farlet" and "uzumab", a common suffix for monoclonal antibodies.
Description
Farletuzumab is a monoclonal antibody that targets the folate receptor alpha (FRA), a protein that is overexpressed in several types of cancer, including ovarian cancer. By binding to FRA, Farletuzumab inhibits the growth of cancer cells and triggers an immune response against them.
Clinical Trials
Farletuzumab has been tested in several clinical trials for the treatment of ovarian cancer. In a phase II trial, it was found to be safe and effective in combination with carboplatin and taxane chemotherapy. A phase III trial is currently underway.
Related Terms
- Monoclonal antibody: A type of protein made in the lab that can bind to substances in the body, including cancer cells.
- Folate receptor alpha (FRA): A protein that is overexpressed in several types of cancer.
- Ovarian cancer: A type of cancer that begins in the ovaries.
- Carboplatin: A chemotherapy drug used to treat ovarian cancer.
- Taxane: A type of chemotherapy drug.
External links
- Medical encyclopedia article on Farletuzumab
- Wikipedia's article - Farletuzumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski